Abstract #0530
Hyperpolarizied 13C MRSI is a better predictor of survival than tumor size in treated glioblastoma
Marina Radoul 1 , Myriam M. Chaumeil 1 , Pia Eriksson 1 , and Sabrina M. Ronen 1
1
Radiology and Biomedical Imaging, UCSF, San
Francisco, CA, United States
Resistance to current therapy and recurrence is not only
common in glioblastoma but also expected. PI3K/Akt/mTOR
signaling pathway, activated in most glioblastoma,
represents an important target in alternative
therapeutic approach. In order to prepare for an
upcoming clinical trial, the goal of this study was to
expand upon previous studies, and to confirm
reproducibility in different model systems and genetic
background, and with a novel PI3K/Akt/mTOR inhibitor. We
used hyperpolarized 13C MRSI, and 1H MRS, and to monitor
the effect of the dual PI3K/mTOR inhibitor XL765
(SAR245409) and TMZ alone or in combination in GS-2
tumors in mice.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
